Abstract

Background:

Bipolar disorder (BD) is a severe, recurrent mood disorder with alternating episodes and persistent cognitive deficits. There are sex differences in episode type, onset age, cognitive dysfunction, and other aspects. Female patients have distinct cognitive impairments. Understanding sex differences is important to assess the condition and optimize treatment. This study investigated the characteristics of cognitive impairment in female patients with BD based on first-episode polarity (manic/hypomanic vs. depressive) and identified associated clinical risk factors.

Methods:

This cross-sectional study enrolled 61 female BD patients (20 with manic/hypomanic onset, 41 with depressive-onset) and 31 healthy controls. Cognitive domains were assessed using the Wisconsin Card Sorting Test (WCST), the Continuous Performance Test (CPT), and the Digit Span Test (DST). Group comparisons and multivariate regression analyses were conducted to evaluate cognitive patterns and clinical correlates.

Results:

(a) Both the manic/hypomanic-onset and the depressive-onset groups showed significantly worse scores compared with the healthy controls; (b) the manic/hypomanic-onset group demonstrated significantly higher scores than the depressive-onset group; and (c) a history of exposure to mental stimuli was associated with reduced patients’ executive function. Additionally, a lower educational level and an early onset were potential risk factors for impaired memory functions.

Conclusions:

Female patients with BDs exhibited cognitive impairments that varied according to first-episode polarity. Those with manic/hypomanic onset exhibited less severe cognitive impairment than those with depressive-onset. Lower educational attainment and earlier disease onset were identified as independent risk factors for cognitive dysfunction.

1. Introduction

Bipolar disorder (BD) is a chronic and debilitating psychiatric condition characterized by recurrent episodes of mania/hypomania and depression, affecting approximately 2% of the world’s population (Goes, 2023). Although mood dysregulation remains the hallmark of BD, accumulating evidence has highlighted cognitive impairment as a core feature that persists across mood states and significantly affects functional outcomes that include occupational performance, social relationships, and quality of life (Chakrabarty et al., 2023; Flaaten et al., 2024). Deficits in executive functioning, attention, memory, and processing speed have been found in the study, with up to 60% of patients exhibiting moderate-to-severe cognitive dysfunction (Semkovska et al., 2019). Despite advancements in understanding BD cognitive profiles, some aspects of the research are still lacking, particularly regarding sex-specific manifestations and the role of illness trajectory in shaping neurocognitive outcomes (Gogos et al., 2023).

Some research has shown sex differences in BD phenomenology, including variations in episode-polarity frequency, comorbidity patterns, and treatment response (Chithra et al., 2023; Lai et al., 2024). Women with BD are disproportionately affected by depressive episodes, rapid cycling, and comorbid endocrine or autoimmune disorders, which are factors that may exacerbate cognitive decline (Martín-Parra et al., 2024). Furthermore, neurobiological research has found that the hormonal fluctuations modulate cognitive function in females individuality (Huang et al., 2023). This point and others need to be further explored in BD populations. In addition, more research is needed to explore the sex differences in cognitive dysfunction among BD patients.

Another research focus is the influence of first-episode polarity (FEP) on the cognitive functions of BD patients (Cavaleri et al., 2025). FEP—categorized as depressive, manic/hypomanic, or mixed—has prognostic significance, with depressive-onset BD associated with delayed diagnosis, higher relapse rates, and poorer functional recovery (Chakrabarty et al., 2021). The results of one study suggested that FEP may also predict distinct neurocognitive profiles, potentially reflecting divergent neurodevelopmental or neurodegenerative pathways (Wang et al., 2023). For instance, manic-onset BD cases have been linked to frontolimbic-circuit abnormalities (Catalan et al., 2024), whereas depressive-onset BD cases may exhibit hippocampal-prefrontal dysconnectivity (Mesbah et al., 2023). However, whether these neural correlates translate to sex-specific cognitive patterns remains unclear.

Some studies have discussed the cognitive-function-impairment characteristics of females with BD (Anticevic et al., 2013; Xu et al., 2021). Female BD patients with first-manic-episode onset may exhibit distractibility in attention, i.e., having difficulty focusing on specific tasks. Their thinking may be rapid but lacks depth and logicality. In terms of memory, they may have a relatively good recall of recent events, but their grasp of details is not accurate. Female BD patients who have a first-depressive-episode onset often experience slowed thinking, i.e., find it difficult to think about problems, and have a reduced reaction speed. Their memory declines, especially in recalling information learned or experienced recently. They have trouble of concentrating and are easily distracted by negative emotions. They perform poorly on tasks that require initiative and planning, such as having difficulty arranging daily life or work affairs. For female patients with mixed-episode onset, their cognitive impairment is more complex. They may simultaneously have various manifestations such as impaired concentration, memory decline, and executive dysfunction (Solé et al., 2022).

The present study addressed cognitive deficiencies through the multidimensional analysis of cognitive impairment in female BD patients by FEP. By integrating neuropsychological assessments, clinical phenotyping, and longitudinal data, we aimed to (a) characterize sex-specific cognitive deficits in BD; (b) evaluate how FEP modulates these cognitive deficits; and (c) identify clinical variables influencing cognitive function. Our study, which focused on female BD patients, may inform personalized intervention strategies, and enhance early evaluation of cognitive function impairment (Bora, 2018).

2. Materials and Methods
2.1 Participants

This cross-sectional study was conducted in the inpatient units of a psychiatric hospital.

2.1.1 Patients Group

The patient group was selected from the inpatient services of a tertiary mental health hospital.

Inclusion criteria: (a) primary diagnosis meeting the BD diagnostic criteria according to the International Classification of Diseases-10 (ICD-10) criteria; (b) Hamilton Depression Scale (HAMD) (24-item version) 7 points for a minimum of 2 weeks; (c) Bech-Rafaelsen Mania Rating Scale (BRMS) 5 points for a minimum of 2 weeks; (d) age 18–60 years old; (e) sex: female; (f) understanding the study questionnaire.

Exclusion criteria: (a) diagnoses consistent with other psychiatric disorders according to ICD-10; (b) severe somatic diseases; (c) comorbid neurological/psychiatric disorders, substance abuse; (d) does not agree to participate in this study.

Patients were divided into two groups according to first-episode polarity. The 61 female BD patients were divided into manic/hypomanic-onset group (n = 20 patients) and depressive-onset group (n = 41 patients).

2.1.2 Healthy Control Group

The healthy controls were staff, students, registrars, and so on. Inclusion criteria: (a) no psychiatric diseases and psychiatric history; (b) age 18–60 years old; (c) sex: female; (d) understand the study questionnaire; (e) agree to participate in this study. A total of 31 healthy female controls were enrolled.

2.2 Disease-Information Collected

An experimenter-designed questionnaire was used to collect disease information, including gender, age, marital status, education level, family history of psychiatric disease, onset age, and history of mental stimuli.

2.3 Assessments
2.3.1 Assessment of Mental Condition

(a) The BRMS mainly assesses the severity of the subject’s manic symptoms. The total score reflects the severity of the disease; higher scores on the scale are significantly associated with more severe disease severity.

(b) The HAMD-24 is used to assess depressive symptoms in patients with psychiatric disorders. There are three versions of this scale, including 17-item, 21-item, and 24-item versions. The 24-item version was used in our study.

2.3.2 Assessment of Cognitive Function

(a) Wisconsin Card Sorting Test (WCST): The WCST consists of 4 stimulus cards and 128 response cards. The WCST is suitable for measuring cognitive function and assessing the level of brain damage to the prefrontal cortex of patients. The WCST reflects subjects’ cognitive functions such as neuropsychological processes, generalization, and working memory. This test takes approximately 20 to 30 min to complete.

Measure indicators of the WCST: Trials Administered (TA), Total Correct Responses (CR), Percent Correct Responses (PCR), Total Errors (TE), Percent Errors (PE), Perseverative Responses (PR), Percent Perseverative Responses (PPR), Perseverative Errors (PE), Percent Perseverative Errors (PPE), Nonperseverative Errors (NPE), Percent Nonperseverative Errors (PNPE), Conceptual Level Responses (CLR), Percent Conceptual Level Responses (PCLR), Categories Completed (CC), Trials to Compete First Category (TCFC), Failure to Maintain Set (FM), Learning to Learn (L-L).

(b) Continuous Performance Test (CPT): CPT is used to measure the areas of attention, vigilance, verbal learning, and memory of samples. The CPT presents several series of single visual stimuli (usually letters or numbers) projected at brief intervals. In our study, the Continuous Performance Test-Identical Pairs (CPT-IP) was used to measure the sustained attention function in patients with BD and healthy controls. In CPT-IP, subjects are asked to respond to targets that are defined as precise repetitions on consecutive trials. In the version of the task of our study, these targets involved two-, three-, or four-digit numbers, which are presented in separate blocks. The task requires both the ability to sustain attention and the ability to update working memory at different levels of working memory load.

Measure indicators of the CPT: CPT-2, CPT-3, CPT-4.

(c) Digit Span Test (DST): DST is a simple yet highly effective method for evaluating short-term and working memory. During the test, the trained examiner reads a sequence of numbers aloud, and the patient is asked to repeat them in the same order. This is known as the “forward digit span”. A more challenging variation, called the “backward digit span”, requires the patient to repeat the numbers in reverse order. The participant must recall them—until they can’t remember the complete sequence, or until they repeat it incorrectly.

Measure indicators of the DST: DST-F = Digit Span Test in the forward condition, DST-B = Digit Span Test in the backward condition, DST-T = total Digit Span Test score. The range of the numerical-sequence length and the scoring rules are presented in the Supplementary Tables 1–3.

2.4 Statistical Analysis

All data were analyzed by SPSS 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables (age, education level, CPT, WCST, etc.) were analyzed by one-way ANOVA. Categorical variables (occupation, family history, etc.) were analyzed using chi-square tests. The least significant difference (LSD) method was used for post-hoc tests. Additionally, analysis of covariance was applied to control for education level, a factor that may affect cognitive function. Spearman correlation analysis was used to examine the correlations between cognitive indicators and clinical variables. Results were expressed as (mean ± SD) or frequency (percentage), respectively. Power analysis and Bonferroni correction were conducted in order to ensure that the sample size, interpret the research results and control the multiple comparison error. p < 0.05 was considered statistically significant.

3. Results
3.1 Demographic and Clinical Characteristics of Participants

The BD patients showed significantly lower educational level (p = 0.003) and higher unemployment rates (p < 0.001) than did the healthy controls. The depressive-onset subgroup demonstrated earlier onset age [(21.5 ± 6.1) vs. (25.3 ± 3.9), p = 0.013], more frequent hospitalizations [(3.5 ± 2.5) vs. (1.7 ± 1.1), p < 0.001] The details were showed in Table 1.

Table 1. Demographic and clinical characteristics of all participants.
Manic group (n = 20) Depressive group (n = 41) Health control group (n = 31) t/F/χ2 p
Age (years) 26.3 ± 0.9 28.0 ± 1.6 26.1 ± 0.9 0.688 0.505
Education level (years) 12.9 ± 1.0 10.9 ± 0.6 14.3 ± 0.7 6.223 0.003
Onset age (years) 25.3 ± 3.9 21.5 ± 6.1 - 2.556 0.013
Admission times 1.7 ± 1.1 3.5 ± 2.5 - –4.110 <0.001***
HAMD-24 2.9 ± 1.3 2.3 ± 1.1 - 2.016 0.048*
BRMS 1.8 ± 0.8 1.6 ± 0.7 - 1.203 0.234
Occupation (n, %) Yes 12 (60.0%) 18 (43.9%) 29 (93.5%) 19.104 <0.001***
No 8 (40.0%) 23 (56.1%) 2 (6.1%)
Marriage state (n, %) Single 6 (30.0%) 15 (36.6%) 12 (38.7%) 4.439 0.350
Married 14 (70.0%) 20 (48.8%) 15 (48.2%)
Divorced 0 (0.0%) 6 (14.6%) 4 (12.9%)
Family history of mental disease (n, %) Positive 6 (30.0%) 13 (31.7%) 0 (0.0%) 12.193 0.002**
Negative 14 (70.0%) 28 (68.3%) 31 (100.0%)
Psychiatric symptom (n, %) Yes 8 (40.0%) 17 (41.5%) - 0.012 0.913
No 12 (60.0%) 24 (58.5%) -
History of mental stimuli (n, %) Yes 3 (15.0%) 13 (31.7%) - 1.939 0.164
No 17 (85.0%) 28 (68.3%) -

Notes: *p < 0.05; **p < 0.01; ***p < 0.001.

HAMD, Hamilton Depression Scale; BRMS, Bech-Rafaelsen Mania Rating Scale.

3.2 Descriptive Statistics of Cognitive Function and ANOVA Analysis in Three Groups [(x¯ ± s), n (%)]

The ANOVA results showed that there were 18 cognitive indicators, 13 cognitive indicators have statistically significant differences between groups (p < 0.05). Nearly half of cognitive indicators had a “large effect” (η2 0.14), indicating that the “grouping” (manic group/depression group/healthy control group) had a statistically significant impact on cognitive functions. The details were showed in Table 2.

Table 2. Descriptive statistics of cognitive function and ANOVA analysis in three groups [(x¯ ± s), n (%)].
Cognition Parameter Groups Among groups SS-between SS-total η2 Effect
Manic group ① Depressive group ② Health control group ③ F p p [(after Bonferroni correction), α (corrected) = 0.0167]
CPT2 2.92 ± 0.19 1.88 ± 0.17 3.44 ± 0.15 25.552 <0.001*** <0.003 45.129 123.723 0.365 L
CPT3 2.03 ± 0.17 1.35 ± 0.14 2.97 ± 0.16 29.963 <0.001*** <0.003 46.617 115.852 0.403 L
CPT4 0.88 ± 0.15 0.54 ± 0.10 1.87 ± 0.16 29.352 <0.001*** <0.003 31.920 80.315 0.397 L
TA 103.80 ± 4.43 115.29 ± 2.64 105.19 ± 3.01 4.243 0.017* 0.051 2599.387 29,863.913 0.087 M
CC 5.20 ± 0.36 3.85 ± 0.34 5.65 ± 0.17 10.137 <0.001*** <0.003 61.831 333.250 0.186 L
CR 63.90 ± 3.20 62.93 ± 2.47 71.84 ± 2.98 3.067 0.052 0.156 1530.389 23,735.163 0.064 M
TE 39.90 ± 6.01 52.22 ± 3.96 30.90 ± 2.97 7.631 0.001*** 0.003 8175.629 55,853.163 0.146 L
PCR 64.15 ± 4.10 57.71 ± 2.81 71.75 ± 2.00 6.684 0.002** 0.006 3478.547 26,638.716 0.131 M
TCFC 15.90 ± 0.97 19.87 ± 2.69 17.90 ± 1.23 0.754 0.474 1.422 216.420 12,703.289 0.017 S
PCLR 59.62 ± 4.62 48.72 ± 3.91 67.78 ± 2.24 7.665 0.001*** 0.003 6528.677 44,433.328 0.147 L
PR 21.95 ± 3.90 30.63 ± 3.43 16.19 ± 3.08 4.951 0.009** 0.027 3776.384 37,717.685 0.100 M
PE 4.90 ± 0.83 9.00 ± 2.04 7.26 ± 1.45 1.128 0.328 0.984 229.221 9274.957 0.025 S
PPE 4.69 ± 0.78 7.45 ± 1.61 6.43 ± 1.18 0.790 0.457 1.371 102.848 5899.103 0.017 S
NPE 35.10 ± 6.02 41.59 ± 4.23 23.65 ± 2.24 5.318 0.007** 0.021 5705.587 53,444.435 0.107 M
FM 0.65 ± 0.21 0.88 ± 0.17 1.23 ± 0.25 1.589 0.210 0.630 4.369 126.728 0.035 S
DST-F 7.65 ± 0.13 6.93 ± 0.20 7.74 ± 0.08 8.261 <0.001*** <0.003 13.897 89.163 0.156 L
DST-B 3.85 ± 0.35 2.93 ± 0.19 4.87 ± 0.22 19.721 <0.001*** <0.003 66.838 217.652 0.307 L
DST-T 11.50 ± 0.40 9.85 ± 0.30 12.61 ± 0.27 21.923 <0.001*** <0.003 137.686 417.163 0.330 L

Notes: *p < 0.05; **p < 0.01; ***p < 0.001.

According to Cohen’s criteria: η2 0.14 indicates a large effect, 0.06 η2 < 0.14 indicates a medium effect, 0.01 η2 < 0.06 indicates a small effect, and η2 < 0.01 indicates a very small effect.

(1) Strong influence indicators (large effect, η2 0.14): 8 cognitive indicators.

① CPT: η2 = 0.365–0.403, p < 0.001, CPT2-4 was the indicator with the largest effect size among all indicators, meaning that “grouping” explain 36.5%–39.7% of the variation in CPT results, and the score was the lowest in the depression group and the highest in the healthy control group, suggesting that the depressive state had the most significant damage to attention.

② DST: Forward condition (DST-F, η2 = 0.156), backward condition (DST-B, η2 = 0.307), and total (DST-t, η2 = 0.330) all had large effects. The score was the lowest in the depressive group and the highest in the healthy control group, verifying the result that “the depressive state is strongly correlated with the decline of working memory”.

③ WCST: The number of false responses (Re, η2 = 0.146) and the percentage of conceptualize level (Rf%, η2 = 0.147) were also large effects. Moreover, the depressive group had the most false responses (52.22 ± 3.96) and the lowest conceptualization level (48.72 ± 3.91), further supporting the “comprehensive impact of the depressive state on cognitive executive function”.

(2) Moderate impact index (0.06 η2 < 0.14): There were 5 cognitive indicators, such as RA (η2 = 0.087, p = 0.017) and the number of correct responses (Rc, η2 = 0.064, p = 0.052). The differences between groups of these indicators are of certain significance, but they are more disturbed by other factors (such as the individual’s basic cognitive level). Further verification is needed in combination with the pairwise comparison results in Table 3.

(3) Weak influence index (η2 < 0.06): There were 6 weak influence index, such as the number of responses required to complete the first classification (Rf, η2 = 0.017, p = 0.474), and the number of persistent errors (Rpe, η2 = 0.025, p = 0.328). There was not statistically significant difference between groups, indicating that “grouping” has almost no effect on such “cognitive detail indicators”.

L, large; M, medium; S, small; CPT, Continuous Performance Test; TA, Trials Administered; CC, Categories Completed; CR, Total Correct Responses; PCR, Percent Correct Responses; TE, Total Errors; PR, Perseverative Responses; PE, Perseverative Errors; PPE, Percent Perseverative Errors; NPE, Nonperseverative Errors; FM, Failure to Maintain Set; PCLR, Percent Conceptual Level Responses; TCFC, Trials to Compete First Category; DST-F, Digit Span Test in the forward condition; DST-B, Digit Span Test in the backward condition; DST-T, total Digit Span Test score; SS, sum of squares.

3.3 Comparison of Cognitive Function among Three Groups [(x¯ ± s), n (%)]

There were significant differences in large effect indicators (such as CPT3, DST-B, and DST-T). The score of the manic group was higher than the depressive group. The cognitive differences of the two groups mainly lie in the complex cognitive executive functions (such as working memory, DST-B, and memory function). The depression group was significantly worse than the manic group and healthy control group in core cognitive functions (attention, working memory, cognitive accuracy) (All p < 0.01 or 0.001). The details were shown in Table 3.

Table 3. Comparison of cognitive function among three groups [(x¯ ± s), n (%)].
Cognition parameter Groups Within groups
T p p (after Bonferroni correction)
Manic group ① Depressive group ② Health control group ③ ①② ①③ ②③ ①② ①③ ②③ ①② ①③ ②③
CPT2 2.92 ± 0.19 1.88 ± 0.17 3.44 ± 0.15 1.047 –0.513 –1.559 <0.001** 0.060 <0.001** <0.001*** 0.181 <0.001***
CPT3 2.03 ± 0.17 1.35 ± 0.14 2.97 ± 0.16 0.681 –0.944 –1.625 0.006* <0.001** <0.001** 0.017* 0.001** <0.001***
CPT4 0.88 ± 0.15 0.54 ± 0.10 1.87 ± 0.16 0.335 –0.991 –1.326 0.099 <0.001*** <0.001** 0.298 <0.001*** <0.001***
TA 103.80 ± 4.43 115.29 ± 2.64 105.19 ± 3.01 –11.493 –1.394 10.099 0.018 0.782 0.017* 0.054 1.000 0.052
CC 5.20 ± 0.36 3.85 ± 0.34 5.65 ± 0.17 1.346 –0.445 –1.792 0.006** 0.377 <0.001** 0.017* 1.000 <0.001***
CR 63.90 ± 3.20 62.93 ± 2.47 71.84 ± 2.98 0.973 –7.939 –8.912 0.822 0.083 0.020* 1.000 0.249 0.060
TE 39.90 ± 6.01 52.22 ± 3.96 30.90 ± 2.97 –12.320 8.997 21.316 0.054 0.179 <0.001** 0.162 0.536 0.001**
PCR 64.15 ± 4.10 57.71 ± 2.81 71.75 ± 2.00 6.435 –7.598 –14.033 0.147 0.104 <0.001** 0.441 0.312 0.001**
TCFC 15.90 ± 0.97 19.87 ± 2.69 17.90 ± 1.23 –3.972 –2.003 1.969 0.231 0.561 0.496 0.694 1.000 1.000
PCLR 59.62 ± 4.62 48.72 ± 3.91 67.78 ± 2.24 10.901 –8.162 –19.063 0.056 0.071 <0.001** 0.168 0.514 0.001**
PR 21.95 ± 3.90 30.63 ± 3.43 16.19 ± 3.08 –8.684 5.756 14.441 0.107 0.307 0.003** 0.320 0.921 0.008**
PE 4.90 ± 0.83 9.00 ± 2.04 7.26 ± 1.45 –4.100 –2.358 1.742 0.139 0.417 0.170 0.418 1.000 1.000
PPE 4.69 ± 0.78 7.45 ± 1.61 6.43 ± 1.18 –2.762 –1.743 1.020 0.213 0.413 0.597 0.638 1.000 1.000
NPE 35.10 ± 6.02 41.59 ± 4.23 23.65 ± 2.24 –6.485 11.455 17.940 0.307 0.088 0.002** 0.922 0.264 0.005**
FM 0.65 ± 0.21 0.88 ± 0.17 1.23 ± 0.25 –0.228 –0.576 –0.348 0.478 0.090 0.216 1.000 0.271 0.648
DST-F 7.65 ± 0.13 6.93 ± 0.20 7.74 ± 0.08 0.723 –0.092 –0.815 0.005** 0.728 <0.001*** 0.015* 1.000 0.001**
DST-B 3.85 ± 0.35 2.93 ± 0.19 4.87 ± 0.22 0.923 –1.021 –1.944 0.011* 0.008** <0.001*** 0.033* 0.023* <0.001***
DST-T 11.50 ± 0.40 9.85 ± 0.30 12.61 ± 0.27 1.646 –1.113 –2.759 0.001** 0.031* <0.001*** 0.003** 0.093 <0.001***

Notes: *p < 0.05; **p < 0.01; ***p < 0.001. The p-values in this table have been adjusted after Bonferroni correction.

(1) Depressive group vs. healthy control group: The difference was the most extensive and significant.

Large effect indicators (such as CPT2, DST-B, R) between the depressive group and the healthy control group were significantly different (All p < 0.001). The score of the depressive group was significantly lower than the healthy control group. This point suggests that the depressive state is highly correlated with the impairment of cognitive function (especially attention and working memory function). The cognitive function of the depressive group with the poorest cognitive performance among three groups.

(2) Manic group vs. healthy control group: There are differences in some indicators, but the damage is mild.

Some large effect index was significant differences (such as CPT2, CPT3). The score of manic group was between the depressive group and the healthy control group. This point indicated that the cognitive impairment of the manic state was weaker than that of the depressive state, with only slight decreases in indicators of attention persistence (CPT-3) and working memory inversion (DST-B).

(3) Manic group vs. Depressive group: The differences were mainly concentrated in core cognitive indicators.

There were significant differences in large effect indicators (such as CPT3, DST-B, and DST-T). the score of the manic group was higher than the depressive group. This point verified that cognitive impairment in the depressive state was more severe than that in the manic state. The cognitive differences of two groups mainly lie in the complex cognitive executive functions (such as working memory, DST-B, memory function).

Further pairings after bonferroni correction: The depressive group was significantly worse than the healthy control group in core cognitive functions (attention, working memory, cognitive accuracy), and the degree of impairment of the depressive group was more severe than the manic group.

3.4 Exploratory Analyses: Correlation Analysis of Cognitive Function Scores

The family history of mental disease was likely to be associated with patients’ executive function (WCST-CC: r = 0.278, p = 0.007; WCST-TE: r = –0.206, p = 0.048; WCST-PCR: r = 0.257, p = 0.013). Additionally, a lower educational level and an early onset of BD could potentially have impaired memory functions (DST-T: r = 0.214, p = 0.041; DST-F: r = 0.356, p = 0.005) (Table 4). The details of Digit Span Test was showed in (Table 5).

Table 4. Analysis of clinical factors affecting cognitive function of female BD patients.
CPT2 CPT3 CPT4 TA CC CR TE PCR TCFC PCLR PR PE PPE NPE FM DST-F DST-B DST-T
Onset type r 0.297 0.400 0.447 –0.060 0.158 0.300 –0.184 0.229 0.087 0.209 –0.211 0.031 0.029 –0.183 0.158 0.105 0.367 0.336
Sig 0.004** 0.000*** 0.000*** 0.569 0.131 0.004** 0.080 0.028* 0.415 0.046* 0.043* 0.771 0.783 0.080 0.133 0.318 0.000*** 0.001**
Onset age r 0.092 0.228 0.168 –0.148 –0.028 –0.079 –0.202 0.131 –0.065 0.231 –0.140 –0.175 –0.074 –0.133 –0.078 0.356 0.200 0.303
Sig 0.481 0.077 0.195 0.255 0.829 0.547 0.118 0.315 0.626 0.074 0.282 0.176 0.572 0.305 0.550 0.005** 0.122 0.018*
Education level r 0.074 0.163 0.143 –0.034 0.052 0.086 –0.089 0.035 0.104 0.076 –0.058 –0.132 –0.101 –0.044 –0.094 0.108 0.211 0.214
Sig 0.481 0.121 0.175 0.745 0.623 0.416 0.400 0.738 0.328 0.471 0.582 0.210 0.337 0.678 0.375 0.306 0.044* 0.041*
HAMD r 0.075 0.010 0.126 –0.057 –0.138 0.065 –0.157 0.145 0.119 0.163 –0.181 –0.208 –0.211 –0.106 –0.059 0.130 0.280 0.294
Sig 0.568 0.940 0.334 0.665 0.290 0.621 0.228 0.267 0.370 0.209 0.162 0.107 0.103 0.417 0.651 0.317 0.029* 0.021*
BRMS r 0.157 0.173 0.194 –0.109 0.154 0.152 –0.182 0.141 0.167 0.154 –0.074 0.027 0.033 –0.173 0.113 0.029 0.287 0.217
Sig 0.227 0.182 0.134 0.403 0.236 0.244 0.161 0.279 0.205 0.235 0.571 0.836 0.802 0.184 0.385 0.825 0.025* 0.093
Occupation r –0.149 –0.163 –0.151 0.010 –0.252 –0.177 0.085 –0.066 –0.141 –0.064 0.013 0.080 0.052 –0.059 –0.038 –0.178 –0.203 –0.230
Sig 0.157 0.120 0.151 0.928 0.015* 0.091 0.423 0.531 0.186 0.544 0.904 0.447 0.622 0.574 0.719 0.090 0.052 0.027*
Family history of mental disease r 0.079 0.043 0.069 –0.162 0.278 0.148 –0.206 0.257 0.013 0.196 –0.157 0.023 0.098 –0.130 0.024 0.048 0.130 0.120
Sig 0.454 0.684 0.515 0.122 0.007* 0.160 0.048* 0.013* 0.900 0.061 0.134 0.825 0.354 0.215 0.817 0.649 0.218 0.253
Psychiatric symptoms r –0.024 –0.063 0.029 0.046 0.017 0.056 0.059 –0.118 –0.026 –0.044 0.151 0.195 0.191 0.009 –0.048 0.163 0.038 0.134
Sig 0.856 0.627 0.822 0.725 0.898 0.669 0.653 0.364 0.843 0.739 0.247 0.132 0.139 0.942 0.716 0.208 0.771 0.302
History of mental stimuli r 0.107 0.064 0.134 –0.118 0.175 0.317 –0.178 0.108 –0.045 0.169 –0.190 –0.077 –0.06 –0.144 –0.024 0.256 0.255 0.295
Sig 0.412 0.627 0.301 0.365 0.177 0.013* 0.170 0.408 0.735 0.192 0.143 0.558 0.644 0.268 0.853 0.047* 0.048* 0.021*

Notes: *p < 0.05; **p < 0.01; ***p < 0.001. Sig, significance.

Table 5. Digit Span Test.
1–Digit Span Test in the forward condition 2–Digit Span Test in the backward condition
(1) Instructions: I will say a sequence of numbers. Please repeat them follow me, okay? (1) Instructions: I will say some numbers. Please repeat them follow me, okay?
(2) Requirements: Read one number per second; only administer Trial 2 of the same item if Trial 1 is failed; regardless of which item is being tested, terminate the test immediately if both trials of an item are failed. (2) Requirements: Read one number per second; only read Trial 2 of the same item if Trial 1 fails; regardless of which item it is, terminate the test if both trials fail.
(3) Scoring Criteria: Award 1 point for a correct response in Trial 1, 1 point for a correct response in Trial 2 of the same item, and 0 points if both trials of the same item are failed. (3) Scoring Criteria: 1 point for a correct response in Trial 1, 1 point for a correct response in Trial 2 of the same item, and 0 points if both trials of the same item fail.
Test Answer Score 0/1 Test Answer Score 0/1
1 1 Trial 3–10 1 1 Trial 7–4
2 Trial 7–4 2 Trial 3–10
2 1 Trial 1–9–3 2 1 Trial 8–2–7
2 Trial 8–2–7 2 Trial 1–9–3
3 1 Trial 4–9–1–6 3 1 Trial 10–6–2–7
2 Trial 10–6–2–7 2 Trial 4–9–1–6
4 1 Trial 6–5–1–4–8 4 1 Trial 5–7–9–8–2
2 Trial 5–7–9–8–2 2 Trial 6–5–1–4–8
5 1 Trial 4–1–9–3–8–10 5 1 Trial 9–2–6–7–3–5
2 Trial 9–2–6–7–3–5 2 Trial 4–1–9–3–8–10
6 1 Trial 10–1–6–4–8–5–7 6 1 Trial 2–6–3–8–2–10–1
2 Trial 2–6–3–8–2–10–1 2 Trial 10–1–6–4–8–5–7
7 1 Trial 7–3–10–5–7–8–5–7 7 1 Trial 6–9–3–2–1–7–10–5
2 Trial 6–9–3–2–1–7–10–5 2 Trial 7–3–10–5–7–8–5–7
8 1 Trial 5–8–4–10–7–3–1–9–6 8 1 Trial 8–2–6–1–10–3–7–4–9
2 Trial 8–2–6–1–10–3–7–4–9 2 Trial 5–8–4–10–7–3–1–9–6
Total Score Total Score
4. Discussion

Our study compared the clinical-disease characteristics and cognitive-function impairment among the different FEPs of female BD patients and with healthy female controls, revealing multidimensional differences in cognitive-function impairment among BD patients under different affective states.

4.1 Chronicity of BD

Compared to the manic-onset group, the depressive-onset group of BD patients exhibited a distinct profile of “earlier onset age—higher admission times—lower occupation rate”. Early onset age may reflect neurodevelopmental vulnerabilities during sensitive periods. For instance, the prefrontal cortex (PFC) is the chief executive officer of the brain, controlling the highest-level cognitive and emotional processes. Dysregulation of PFC synaptic transmission is strongly linked to affective disturbance, social deficits, and memory loss in mental disorders (Solé et al., 2017). Recurrent hospitalizations (3.5 ± 2.5 episodes) suggest a relapsing-remitting course of the depressive-onset BD patients, and potentially exacerbated neuroprogressive damage through a “relapse–cognitive decline–functional deterioration” cycle (Yan and Rein, 2022). The lower occupation rate in the depressive-onset group suggested severe social dysfunction, likely mediated by deficits in working memory and sustained attention, which impaired occupational performance. Prolonged unemployment may serve as an indicator of severe cognitive impairment.

4.2 Memory and Attention

The FEP depressive group exhibited significantly lower performance on the sustained-attention tasks (CPT-2, CPT-3, CPT-4) and the working-memory tasks (DST-F, DST-B, DST-T) than did the healthy control group (Table 2). However, they performed better in long-term memory retrieval tasks, such as recall efficiency and recall correctness, showing a dissociation pattern of “impaired attention control and relatively preserved memory retrieval”. This phenomenon can be explained by dual-process theories in cognitive neuroscience (Spunt, 2015): (a) Attention control networks impaired: sustained attention relies on top-down regulation by the dorsolateral prefrontal cortex (DLPFC). Glucose metabolism reduced in DLPFC during depressive states diminishes inhibitory control over some stimulus factors, increasing error rates in CPT tasks (Meng et al., 2025). (b) Dissociation between memory encoding and retrieval: enhanced response accuracy in the depressive-onset group may relate to preferential processing of negative stimuli. Depressive-state patients exhibited heightened attention bias toward sad faces, leading to the wrong encoding of emotional information. Focusing on sad faces was associated with recent negative life events or other factors (Klawohn et al., 2020).

In contrast, the manic-onset group showed minimal cognitive differences from healthy controls, with slight advantages only in DST-B and CPT-2. This may reflect dopamine-system hyperactivity during mania, enhancing memory encoding, especially memory of novel events (Wang et al., 2023). However, no significant correlation was found between BRMS scores and cognition impairment, suggesting that the hypomania state affects cognition only in specific dimensions, possibly modulated by symptom severity.

Our research found that there were differences in cognitive function among patients with BD of different FEPs. The various indicators of CPT and DST, as well as CC of WCST in the depression-onset group and the mania/hypomania-onset group, were all lower than those in the normal control group. Those indicators in the depression-onset group were all lower than those in the mania/hypomania-onset group, suggesting that the degree of cognitive-function impairment in the depression-onset group was more severe than that in the mania/hypomania-onset group, especially in attention function and memory function. We also found similar characteristics of cognitive impairment in an earlier study (Wang et al., 2023).

4.3 Gene-Environment Interactions​

A significantly higher family history of mental disorders (30%–31.7%) in patient groups supports possible genetic factors affecting cognitive impairment in BDs. BD has high heritability, so unaffected first-degree relatives and offspring of patients with BD present with certain cognitive dysfunctions (de la Serna et al., 2016). Genetic studies have also indicated that environmental contexts are risk factors for the onset, course, and cognitive impairment of bipolar-spectrum disorders.

Higher education level correlated positively with DST-B and DST-T, suggesting that higher education may enhance synaptic density and reduce cognitive impairment (Jansen et al., 2021). Notably, occupation status negatively correlated with CC, possibly indicating that the demands of the occupational state help maintain cognitive function. One study found that cognitive ability is robustly positively correlated with higher occupational status and enhanced job performance. Cognition (which encompasses processing speed, reasoning, and working-memory capacities) is essential for performing complex and cognitively demanding tasks that entail novel problem-solving and rapid learning (Aichele et al., 2024). This point supports combined “social intervention - cognitive rehabilitation” strategies, in which vocational training could delay cognitive decline. Of course, we believe that the first-episode polarity as a predictor of cognitive impairment in BD may be a clinical hypothesis.

4.4 Early Identification and Intervention of Cognitive Impairment

It is important to set up the cognitive screening (e.g., CPT and DST) to identify attention and working-memory deficits, enabling early interventions by cognitive behavior rehabilitation (CBR) to reduce the degree of the cognitive impairment (Razavi et al., 2024; Tsapekos et al., 2023). It is a better intervention plan for improving cognitive impairment by drug combination with physical therapy. Some antidepressants with minimal cognitive side effects and adjunct Repetitive Transcranial Magnetic Stimulation (rTMS) (to enhance prefrontal excitability) may improve working memory. Lifestyle modifications (diet, physical activity, sleep and stress management) (Simjanoski et al., 2023), psychological and behavioral intervention therapy (cognitive remediation therapy, CRT) may alleviate cognitive impairment, enhance cognition, and functioning (Strawbridge et al., 2021).

4.5 Limitations

The sample size of this study was relatively small, and the sample was limited to only one psychiatric hospital in China. Further validation of the clinical characteristics of cognitive impairment in BD patients is required in larger cohorts. The difference in sample size among subgroups affects statistical power and limits generalizability. We did not conduct a power analysis for the sample size. All samples were inpatients (no outpatients); this is a potential recruitment bias. Due to the limited sample size, not all potential confounding factors (e.g., age, number of hospitalizations) could be controlled, and future studies are needed for further validation. The cross-sectional data cannot distinguish between disease state, episode period, and remission period. The correlation results only reflect the co-occurrence relationship between variables and do not indicate the causal direction. In the future, longitudinal studies should be used to track cognitive function level recovered during remission are required. The structural relationships among variables can be further explored through longitudinal studies or Path analysis.

5. Conclusions

Our study evaluated the cognitive-function clinical characteristics of female BD patients and clarified that the BD patient population generally has cognitive impairments. Among BD patients, cognitive impairments in the first-episode depression group (including attention function, executive function, and memory function) are more severe than those in the first-episode mania group. The study also found adverse factors affecting cognitive impairments, including a history of mental stimulation, low educational level, and early age of onset. Based on the above findings, this study emphasized that early screening and targeted intervention for cognitive impairments in patients with BD are of significant clinical necessity.

Due to the cross-sectional design, the correlational results cannot infer causality, and longitudinal studies are needed for future validation.

Availability of Data and Materials

The data during the current study aren’t publicly available due to the fact that they contain sensitive information about research participants, but are available from the corresponding authors on reasonable request.

Author Contributions

ZGW, WZ and KL designed the research study. ZGW, XL, HS, CW, LG, ZJ, ZW and JD performed the research. XL and HS analyzed the data. ZGW and HS drafted the manuscript. All authors contributed to the critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

The study was carried out in accordance with the guidelines of the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Shandong Daizhuang Hospital (approval number: 2023KY025-1). All patients or their families gave their informed consent for inclusion before they participated in the study.

Acknowledgment

We thank all the study participants and researchers who participated in the data collection.

Funding

This work was supported by Key Research and Development Program of Jining Science and Technology Bureau (2023YXNS053).

Conflict of Interest

The authors declare no conflict of interest.

Supplementary Material

Supplementary material associated with this article can be found, in the online version, at https://doi.org/10.31083/BP44839.

References

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.